Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YL201 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Dose Exploration (Part 1) | EXPERIMENTAL | Multiple dose levels of YL201 will be explored in combination with tarlatamab administered intravenously (IV) at a fixed dose using one-step dosing. |
| Dose Expansion (Part 2) | EXPERIMENTAL | YL201 will be administered at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV at a fixed dose. |
| Triplet Combination (Part 3) | EXPERIMENTAL | YL201 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) administered IV at a fixed dose. |
| Name | Type | Description |
|---|---|---|
| YL201 | DRUG | YL201 will be administered as an IV infusion. |
| Tarlatamab | DRUG | Tarlatamab will be administered as an IV infusion. |
| Durvalumab | DRUG | Durvalumab will be administered as an IV infusion. |
Inclusion Criteria: * Participants ≥ 18 years of age (or legal adult age within country) at time of signing informed consent. * Participants with histologically or cytologically confirmed ES-SCLC. * For Parts 1 and 2, subjects must have ES-SCLC that has progressed or recurred following at least 1 p...
Top 20 of 84 competitors
YL201 is an investigational small molecule being studied for the treatment of Small Cell Lung Cancer (SCLC). It is currently in Phase 1 clinical development, evaluated in combination with tarlatamab, with or without an anti-PD-L1 agent, in participants with extensive stage SCLC.
YL201 targets B7-H3, a protein involved in tumor biology. By targeting B7-H3, YL201 is designed to interfere with this protein's activity in cancer cells. It is being studied as part of combination therapy for Small Cell Lung Cancer.
YL201 is being developed by Amgen Inc. (NASDAQ: AMGN). The company is conducting a Phase 1 clinical trial of YL201 in combination with tarlatamab for the treatment of extensive stage Small Cell Lung Cancer.
YL201 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 1 trial is active but not recruiting participants, with a planned enrollment of 29 patients.
YL201 is being studied in one Phase 1 clinical trial, identified as NCT06898957. This trial evaluates YL201 in combination with tarlatamab, with or without an anti-PD-L1 agent, in participants with extensive stage Small Cell Lung Cancer. The study is active but not recruiting.
No, YL201 is not the same as tarlatamab. YL201 is a small molecule targeting B7-H3, while tarlatamab is a separate investigational agent. In the ongoing Phase 1 trial, YL201 is being studied in combination with tarlatamab for Small Cell Lung Cancer.